Observational studyDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2014
[Reliability and safety of intravitreal Ozurdex injections. The ZERO study].
Observational study in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Suprachoroidal implantation of corticosteroid slow release implants for the treatment of cystoid macular edema.Scientific reports · 2025Article
- Management of ocular hypertension following intravitreal dexamethasone implant (ozurdex).American journal of ophthalmology case reports · 2025Article
- Suprachoroidal Delivery of Corticosteroid Slow-Release Implants for the Treatment of Cystoid Macular Edema.Klinische Monatsblatter fur Augenheilkunde · 2025Article
- Anterior segment migration of intravitreal dexamethasone implant in a patient with scleral fixation intraocular lens implant: a case report.Journal of surgical case reports · 2024Article
- Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Anterior segment complications after dexamethasone implantations:real world data.International ophthalmology · 2023Article
- Intralenticular Ozurdex injection in an eye with thicker lens and the therapeutic effect maintained for 15 months.Heliyon · 2022Article
- Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion.Scientific reports · 2021Article
- Dexamethasone intravitreal implant in the crystalline lens: a case report.Arquivos brasileiros de oftalmologia · 2020Article
- Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up.Journal of ophthalmology · 2020Article
- Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Surgical Management of Complications after Dexamethasone Implant.Case reports in ophthalmological medicine · 2020Article
- Iatrogenic crystalline lens injury during intravitreal injection of triamcinolone acetonide: A report of two cases.World journal of clinical cases · 2019Article
- Dexamethasone Intravitreal Implant Injection in Eyes with Comorbid Hypotony.Ophthalmology. Retina · 2019Article
- Iatrogenic intralenticular broken steroid implant: a case report.Journal of medical case reports · 2019Article
- Drug-resistant coagulase-negative staphylococcal endophthalmitis following dexamethasone intravitreal implant.Indian journal of ophthalmology · 2017Article
- Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017Article
- Ozurdex completely located inside a crystallized lens - Results of 14 months.American journal of ophthalmology case reports · 2016Article
- [Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Article
- Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince July 2010 Ozurdex® is approved in Germany for treatment of macular edema from retinal vein occlusion (RVO). The objective of this observational study was a systemic summary and analysis of clinical experience regarding complications and side effects of intravitreal administration of dexamethasone. PATIENTS AND
methodsIn a retrospective, multicenter study conducted at 10 centers, 342 eyes with RVO were treated with intravitreal dexamethasone (Ozurdex®, Allergan). After treatment the patients were followed-up over a period of 8 months and intraoperative, perioperative and postoperative complications, such as elevated intraocular pressure and dislocation of implants were systematically recorded.
resultsNo infections, endophthalmitis, perioperative hypotension, intraoperative lens injuries or retinal detachment occurred. Elevated intraocular pressure was the most common complication accounting for nearly 20 %. In 9 % of patients the intraocular pressure increased by more than 10 mmHg compared to baseline and in 6 patients to > 35 mmHg. In cases of known glaucoma intraocular pressure elevation was not significantly more frequent compared to non-glaucoma patients. In four cases a progression of lens opacity led to phacoemulsification and two implant dislocations in the anterior chamber required surgical repositioning in the vitreous cavity. In two cases a postinterventional macular hole was observed.
conclusionsIn the clinical routine Ozurdex treatment has proven to be a therapy method with minimal side effects. In Ozurdex administration intraocular pressure elevation was observed as the most common side effect; however, this generally did not require surgical intervention. Caution is advised in patients with an anterior chamber lens and iridectomy. Macular holes as a rare complication might result from vitreous traction during the administration process. In summary, even in the clinical routine application of Ozurdex the complication rate was not higher than in registration studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.